SHZ · 002294.SZ
Shenzhen Salubris Pharmaceuticals Co., Ltd.
CN¥29.89-CN¥0.36 (-1.19%)
Shenzhen Salubris Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 57.9% below the high.
Loading market information…
SHZ · 002675.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 20.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.’s forward annual dividend is CN¥0.08 per share, paid annual. The forward yield is 0.63% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.’s next earnings report is currently expected on Apr 23, 2027, with estimated earnings per share of CN¥0.18. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Yantai Dongcheng Pharmaceutical Group Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 01:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥659.38M |
| Q2 2025 | Aug 15, 2025 | CN¥0.08+188.89% vs estimate | CN¥697.00M |
|---|
| Q1 2025 | Apr 29, 2025 | CN¥0.03-81.25% vs estimate | CN¥686.93M |
|---|
| Q4 2024 | Feb 26, 2025 | CN¥0.02-74.3% vs estimate | CN¥706.50M-0.07% vs estimate |
|---|
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥29.89-CN¥0.36 (-1.19%)
Shenzhen Salubris Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 57.9% below the high.
CN¥8.08+CN¥0.09 (+1.13%)
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.75% below the high.
CN¥6.05+CN¥0.31 (+5.4%)
Changzhou Qianhong Biopharma CO.,LTD’s quoted price sits in the lower half of its reported 52-week range, 35.91% below the high.
CN¥10.49-CN¥0.22 (-2.05%)
Sichuan Huiyu Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.47% below the high.
CN¥12.23+CN¥0.08 (+0.66%)
Shandong Xinhua Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 34.6% below the high.
CN¥2.85-CN¥0.04 (-1.38%)
Hunan Er-Kang Pharmaceutical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 44.23% below the high.
CN¥26.22CN¥0.00 (0.0%)
Jiangsu Jibeier Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.09% below the high.
CN¥12.47-CN¥0.32 (-2.5%)
Jiangsu Lianhuan Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.36% below the high.
